{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:59:55Z","timestamp":1790398795170,"version":"4.1.0"},"reference-count":19,"publisher":"International Research and Cooperation Association for Bio & Socio-Sciences Advancement (IRCA-BSSA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["DD&amp;T"],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.5582\/ddt.2026.01054","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:09:54Z","timestamp":1787004594000},"page":"349-353","source":"Crossref","is-referenced-by-count":0,"title":["Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework"],"prefix":"10.5582","volume":"20","author":[{"given":"Tian-Ge","family":"Qin","sequence":"first","affiliation":[{"name":"Department of Medical Technology, Clinical College of Anhui Medical University, Hefei, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Union Hospital, Fujian Medical University, Fuzhou, Fujian, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3542","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Ma YN, Karako K, Song P, Xia Y. Can the herpes zoster vaccination be a strategy against dementia? Drug Discov Ther. 2025; 19:124-128.","DOI":"10.5582\/ddt.2025.01032"},{"key":"2","unstructured":"2. World Health Organization. Dementia. <i>https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia<\/i> (accessed June 18, 2026)."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Cummings J, Zhou Y, Lee G, Zhong K, Fonseca J, Cheng F. Alzheimer&apos;s disease drug development pipeline: 2024. Alzheimers Dement (N Y). 2024; 10:e12465.","DOI":"10.1002\/trc2.12465"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. van Dyck CH, Swanson CJ, Aisen P, <i>et al<\/i>. Lecanemab in early Alzheimer&apos;s disease. N Engl J Med. 2023; 388:9-21.","DOI":"10.1056\/NEJMoa2212948"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sims JR, Zimmer JA, Evans CD, <i>et al<\/i>. Donanemab in early symptomatic Alzheimer disease: The TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA. 2023; 330:512-527.","DOI":"10.1001\/jama.2023.21109"},{"key":"6","unstructured":"6. DailyMed. Acitretin capsule. <i>https:\/\/dailymed.nlm.nih.gov\/dailymed\/<\/i> (accessed June 18, 2026)."},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Lammich S, Kojro E, Postina R, Gilbert S, Pfeiffer R, Jasionowski M, Haass C, Fahrenholz F. Constitutive and regulated alpha-secretase cleavage of Alzheimer&apos;s amyloid precursor protein by a disintegrin metalloprotease. Proc Natl Acad Sci U S A. 1999; 96:3922-3927.","DOI":"10.1073\/pnas.96.7.3922"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Kuhn PH, Wang H, Dislich B, Colombo A, Zeitschel U, Ellwart JW, Kremmer E, Rossner S, Lichtenthaler SF. ADAM10 is the physiologically relevant, constitutive alpha-secretase of the amyloid precursor protein in primary neurons. EMBO J. 2010; 29:3020-3032.","DOI":"10.1038\/emboj.2010.167"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Postina R, Schroeder A, Dewachter I, Bohl J, Schmitt U, Kojro E, Prinzen C, Endres K, Hiemke C, Blessing M, Flamez P, Dequenne A, Godaux E, van Leuven F, Fahrenholz F. A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. J Clin Invest. 2004; 113:1456-1464.","DOI":"10.1172\/JCI20864"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Saftig P, Lichtenthaler SF. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain. Prog Neurobiol. 2015; 135:1-20.","DOI":"10.1016\/j.pneurobio.2015.10.003"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tippmann F, Hundt J, Schneider A, Endres K, Fahrenholz F. Up-regulation of the alpha-secretase ADAM10 by retinoic acid receptors and acitretin. FASEB J. 2009; 23:1643-1654.","DOI":"10.1096\/fj.08-121392"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Muller UC, Deller T, Korte M. Not just amyloid: Physiological functions of the amyloid precursor protein family. Nat Rev Neurosci. 2017; 18:281-298.","DOI":"10.1038\/nrn.2017.29"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Cramer PE, Cirrito JR, Wesson DW, Lee CYD, Karlo JC, Zinn AE, Casali BT, Restivo JL, Goebel WD, James MJ, Brunden KR, Wilson DA, Landreth GE. ApoE-directed therapeutics rapidly clear beta-amyloid and reverse deficits in AD mouse models. Science. 2012; 335:1503-1506.","DOI":"10.1126\/science.1217697"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, Pontecorvo M, Devous M, Tang A, Bena J. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene in moderate Alzheimer&apos;s disease. Alzheimers Res Ther. 2016; 8:4.","DOI":"10.1186\/s13195-016-0173-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U, Fahrenholz F. Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein. Neurodegener Dis. 2012; 10:224-228.","DOI":"10.1159\/000334300"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Endres K, Fahrenholz F, Lotz J, Hiemke C, Teipel S, Lieb K, Tuscher O, Fellgiebel A. Increased CSF APPs-alpha levels in patients with Alzheimer disease treated with acitretin. Neurology. 2014; 83:1930-1935.","DOI":"10.1212\/WNL.0000000000001017"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. dos Santos Guilherme M, Stoye NM, Rose-John S, Garbers C, Fellgiebel A, Endres K. The synthetic retinoid acitretin increases IL-6 in the central nervous system of Alzheimer disease model mice and human patients. Front Aging Neurosci. 2019; 11:182.","DOI":"10.3389\/fnagi.2019.00182"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rosales Jubal E, Schwalm M, Dos Santos Guilherme M, Schuck F, Reinhardt S, Tose A, Barger Z, Roesler MK, Ruffini N, Wierczeiko A, Schmeisser MJ, Schmitt U, Endres K, Stroh A. Acitretin reverses early functional network degradation in a mouse model of familial Alzheimer&apos;s disease. Sci Rep. 2021; 11:6649.","DOI":"10.1038\/s41598-021-85912-0"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Khezri MR, Mohebalizadeh M, Ghasemnejad-Berenji M. Therapeutic potential of ADAM10 modulation in Alzheimer&apos;s disease: A review of the current evidence. Cell Commun Signal. 2023; 21:60.","DOI":"10.1186\/s12964-023-01072-w"}],"container-title":["Drug Discoveries &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:29:57Z","timestamp":1790396997000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ddt\/20\/4\/20_2026.01054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5582\/ddt.2026.01054","relation":{},"ISSN":["1881-7831","1881-784X"],"issn-type":[{"value":"1881-7831","type":"print"},{"value":"1881-784X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"2026.01054"}}